Moderna, Inc. $MRNA Position Lifted by BNP PARIBAS ASSET MANAGEMENT Holding S.A.

Key Points

• BNP PARIBAS ASSET MANAGEMENT increased its stake in Moderna by 66.3%, acquiring 48,529 additional shares, bringing its total holdings to 121,727 shares worth approximately $3.46 million.
• Moderna's stock has a market cap of $10.93 billion, trading at about $28.09, with a consensus rating of "Hold" from analysts.
• For the last quarter, Moderna reported an earnings per share (EPS) of ($2.13), exceeding expectations, while its revenue fell 41.1% year-over-year to $142 million.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 66.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 121,727 shares of the company's stock after acquiring an additional 48,529 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.'s holdings in Moderna were worth $3,458,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in MRNA. Deutsche Bank AG lifted its position in shares of Moderna by 54.7% in the 4th quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock worth $78,756,000 after buying an additional 669,614 shares during the last quarter. Tang Capital Management LLC bought a new position in shares of Moderna in the 4th quarter worth about $12,474,000. Bank of New York Mellon Corp lifted its position in shares of Moderna by 1.8% in the 1st quarter. Bank of New York Mellon Corp now owns 1,918,248 shares of the company's stock worth $54,382,000 after buying an additional 34,034 shares during the last quarter. Wealthfront Advisers LLC lifted its position in shares of Moderna by 143.3% in the 1st quarter. Wealthfront Advisers LLC now owns 31,018 shares of the company's stock worth $879,000 after buying an additional 18,268 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Moderna by 12.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock worth $74,557,000 after buying an additional 285,662 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Royal Bank Of Canada reduced their price target on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Morgan Stanley restated an "equal weight" rating and issued a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. Wells Fargo & Company restated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Citigroup initiated coverage on shares of Moderna in a research report on Friday, August 1st. They issued a "neutral" rating and a $40.00 price target on the stock. Finally, William Blair reaffirmed a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Moderna currently has a consensus rating of "Hold" and a consensus target price of $43.59.

Moderna Trading Up 0.2%

Moderna stock opened at $28.09 on Tuesday. The stock has a market cap of $10.93 billion, a price-to-earnings ratio of -3.73 and a beta of 1.83. The company's 50-day moving average price is $29.20 and its two-hundred day moving average price is $29.27. Moderna, Inc. has a 52 week low of $23.15 and a 52 week high of $91.99.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, beating the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. Moderna's quarterly revenue was down 41.1% on a year-over-year basis. During the same quarter last year, the company earned ($3.33) EPS. Research analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.